Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 346

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 346
---
 2024. |

| (2) | Brian                                                                                                                                       
 G. Atwood served as Chairman and Chief Executive Officer of the Company from February 2024 to September 2024, and previously served as      
 Chairman of PBAX until the closing of the Business Combination in February 2024. Mr. Atwood is currently a member of the board of directors 
 of the Company and serves as a trustee of Atwood-Edminster Trust dtd 4-2-2000. GVN, LLC, is a limited liability company of which the        
 sole member is the Atwood-Edminster Trust dtd 4-2-2000, and of which Brian G. Atwood and Lynne H. Edminster are the managers.               |

| (3) | Chris Ehrlich has served as the Chairman and Chief Executive Officer of the Company since December 2024, and previously served as (i) interim Chairman and Chief Executive Officer of the Company from October 2024 to November 2024, (ii) Vice Chairman of the board of directors of the Company from February 2024 to September 2024, and (iii) the Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024. |

During the three months ended March 31, 2025 and
for the period from February 14, 2024 to March 31, 2024, the Company incurred a consulting fee of $ and $ to a member of the
Company’s board of directors, respectively.

NOTE 14 – SUBSEQUENT EVENTS During the period from April 1, 2025 to May 14, 2025, 23shares of Series B Preferred Stock were converted into 3,164shares of Common Stock. The conversion ratio was based on the Series B Certificate of Designations and reflected the applicable Alternate Conversion Price. During the period from April 1, 2025 to May 14, 2025, 520shares of Series C Preferred Stock were converted into 104,000shares of Common Stock. The conversion ratio was based on the Series C Certificate of Designations and reflected the applicable Alternate Conversion Price. During the period from April 1, 2025 to May 14, 2025, the Company sold 9,903shares of Common Stock of the Company pursuant to the New Keystone Purchase Agreement for net proceeds of $ 124,353. On April 9, 2025, the Company issued 10,